About MEAJO | Editorial board | Search | Ahead of print | Current Issue | Archives | Instructions to authors | Online submission | Subscribe | Advertise | Contact | Login 
Middle East African Journal of Ophthalmology Middle East African Journal of Ophthalmology
Users Online: 423   Home Print this page Email this page Small font sizeDefault font sizeIncrease font size
CASE REPORT
Year : 2011  |  Volume : 18  |  Issue : 3  |  Page : 243-245

Response of diabetic papillopathy to intravitreal bevacizumab


King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia

Correspondence Address:
Arif O Khan
King Khaled Eye Specialist Hospital, PO Box 7191, Riyadh 11462
Saudi Arabia
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0974-9233.84056

Rights and Permissions

Diabetic papillopathy is an uncommon hyperemic optic disc swelling that occurs in patients with long-standing diabetes, is typically self-resolving with minimal effect on vision, and is likely ischemic in origin. The purpose of the current report is to document the response of diabetic papillopathy to intravitreal injection of bevacizumab (Avastin, Genentech Inc, San Francisco, California, USA), a humanized monoclonal antibody to vascular endothelial growth factor.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed3590    
    Printed157    
    Emailed0    
    PDF Downloaded155    
    Comments [Add]    
    Cited by others 5    

Recommend this journal